Modern Synthesis Raises $5.5M to Grow High-Performance Biomaterials from Microbes
London-based biotechnology company Modern Synthesis has raised $5.5 million in an oversubscribed funding round led by Extantia Capital, with additional investments from Artesian and Collaborative Fund. The financing will support the company’s efforts to scale production at its pilot facility and meet growing demand from fashion brands seeking sustainable material alternatives. Fashion brands are expected to face a shortage of 133 million tonnes of low-impact raw materials by 2030 due to increasing regulatory pressure to decarbonize. Modern Synthesis aims to address this gap with its biomaterial technology, which uses nanocellulose—a fibre derived from microbial fermentation—to create alternatives to animal leather, synthetic leather, and plastic-coated textiles. The company’s proprietary process leverages the strength of nanocellulose, which is significantly stronger than steel at the nanofiber level, to …